advancing preparation commercial WM. is Chad. for of launch potential our you, Commercial team iopofosine the in Thank
Importantly, FDA of approval. a our strategy for we launch upon and progress make continue commercialization execute to the successful iopofosine, goal ensuring supporting
journey very radiation the market recent nuclear physicians. and and of evaluation included findings most of product and are which WM by We encouraged segmentation iopofosine's with research medicine projects, profile research oncologists an our evaluation from patient
Iopofosine's which choice product exceptionally includes patient findings for with to Key WM an patient treatment was new profile journey need options participation for hematologists. our and in intent also fixed and rate work important active a from prescribe therapies. showed treatment drivers, high for given
since medicine of oncologists utilization. also have very with nuclear iopofosine's profile enthusiastic was they radiation key and for We radiotherapeutics. existing nuclear of were use medicine Radiation versus iopofosine's simplicity physicians review radiotherapy They are engaged physicians and positive. oncologists stakeholders
storage Iopofosine's supports best-in-class Interactions group. features such and ease community short utilization that, the significant long administration as setting. radiotherapeutic next-generation outpatient that of is stakeholder and life further a differentiators were both hospital iopofosine no as significant regarded time, will secure if key infusion in required stakeholders our belief key dosimetry, this with by approved, these
leadership. go-to-market the model successful are experienced and We will for of establishing goal building market with commercial a framework WM a in our support team selectively that
that to awareness utilizing for experience ensure be and decision-making activation, radiotherapy both site will experience We providers. claims will right the first data that iopofosine with drive brand patients treatment support is the and
initiated have strategy. market additional value support and will research projects further pricing product that messaging positioning, payer We
highly We WM commercial continue model. further and data a build to efficient to supporting out understand market cost-effective capabilities the
with with real to market significant leadership, We believe an need, active WM no with a approval. market concentrated opportunity very provides share a unmet utilizing a is attractive capture competition market limited is promotion FDA high
X. Turning to Slide
capture has and claims opportunities approximately current to assuming X valued at the the market billion marketing WM total show relapsed/refracting market share, estimates patient compelling third-party approval. Iopofosine Our billion. $X.X to with U.S. be $X very
therapies FDA in exists the relapsed/refractory share setting readily same approved the capture high burdened lack line market, earlier share these unmet be an to due the XX% greater relapsed/refractory of which or market. existing can X% than from to or current retreated patient by third of Iopofosine not line capture to in and opportunity are first in patients with need. positioned options. treatment the The of is similar Nearly cannot Greater are be promoted.
exhausted market, Second, we patients, line options. prevalent X,XXX greater expand is or patients to This second approximately for the X,XXX Approximately the which treatment third iopofosine. is patients. the could have believe X,XXX opportunity
or novel by result, intolerant WM treatment. expansion a ineligible opportunity remain This iopofosine capture a of patient as fast As market allow either current market could patients treatments.
WM. of no X, data On Slide care claims our there established demonstrate is standard in
FDA-approved XX% greater drugs been new is As of who therapy. half, second as received stated, no the BTKi rechallenging non-FDA BTKi again has of the patients third-line a in as limited mechanism function over options in This than a action nearly a setting mainly and line in approved treatment XX% relapsed/refractory of receive decade. previously there patients are
mechanism action active strong with share significant its can clinical profile Iopofosine market. iopofosine this promotion capture in with of with a along Cellectar's novel of
of rechallenged patients lines. X, with significant XX% existing that received these and of approximately XX% Slide According therapies. claims the and confirms claims data, patients bendamustine, third-line later are chemotherapeutic in market drug data to consistent chemotherapy recycling of
only is greater the than rituximab class FDA-approved drugs received prior There in in X patients more line of are after approved X,XXX retreated zanubrutinib. class, third only Approximately rituximab XX% and ibrutinib therapies which or one and setting. with this exposure. And includes
third Third-party data BTKi also BTKis the setting. validates claims retry of approximately line greater or patients XX% in
XX% of retreated As previously therapy. greater X,XXX patients stated, after that third in been nearly to prior exposure have line the same setting or
consistent lack opinion the outcomes. options. therapies better recycling to of for of underscores need fixed unmet therapy key efficacy for therapies According need, is express a action, novel and of market characteristics and not existing treaters course all promoted. due mechanism treatment actively the WM The leadership are and a of Market to research, nearly
for This We believe Pricing care million. stated for could therapies and provides with premium FDA continuous significant other these evaluation preferences therapies over of total approval. cost cost optionality upon pricing. $X iopofosine address iopofosine can analog
As initiated that work recommended noted the pricing optimal price. we provide have will earlier, our
of Slide diagnosed high-level or of XX% execution. line accounts. greater to approach a only patients second patients treated highly in market The Lastly, our with concentrated is in XX of is XX% illustration states. approximately XXX X are WM
at commercial will the This time quickly to concentrated market with to a and right supports the patient capture account strategy drive customer optimize share nature the leverage geographic of share. of voice awareness segmentation and that right
iopofosine in In a leader with WM. to efforts commercial look successful conclusion, of updates. market share objective advancing providing We additional planning launch the as our establishing forward are and executing a
to over manufacturing Jarrod Jarrod? will to and highlight now our I Longcor call the turn distribution.
